TOKIN: Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population (H-48054)

TOKIN: Safety And Efficacy Of Tyrosine Kinase Inhibitor Cessation For Chronic Myeloid Leukemia Patients With Stable Molecular Response In A Real World Population

This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population. Participants who have achieved complete molecular remission will stop taking their drug for CML (called a tyrosine kinase inhibitor or TKI), and will be followed closely to see if their CML returns. The study staff will collect blood samples at the participant’s normal post-treatment follow-up schedule. Participants will be asked to complete questionnaires. The purpose is to see how long patients will remain cancer free after stopping TKI treatment, and how stopping TKI affects patients’ quality of life. 

For more information: https://clinicaltrials.gov/study/NCT04626024